"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 2 | 2 | 4 |
| 2001 | 2 | 2 | 4 |
| 2002 | 2 | 4 | 6 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 5 | 2 | 7 |
| 2007 | 1 | 3 | 4 |
| 2008 | 3 | 2 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 4 | 6 |
| 2012 | 4 | 3 | 7 |
| 2013 | 9 | 3 | 12 |
| 2014 | 4 | 0 | 4 |
| 2015 | 4 | 2 | 6 |
| 2016 | 0 | 5 | 5 |
| 2017 | 4 | 1 | 5 |
| 2018 | 4 | 1 | 5 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 3 | 6 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials. 2023 05; 296:122062.
-
Size matters in non-canonical inflammasome activation and cell-mediated immunity. Cell Rep Med. 2023 01 17; 4(1):100904.
-
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 Nov 10; 40(32):3741-3749.
-
Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants. Sci Rep. 2022 06 02; 12(1):9198.
-
Robust tolerogenic dendritic cells via push/pull pairing of toll-like-receptor agonists and immunomodulators reduces EAE. Biomaterials. 2022 07; 286:121571.
-
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
-
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Biomaterials. 2021 11; 278:121159.
-
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021 07; 35(7):743-767.
-
Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response. Sci Rep. 2021 03 18; 11(1):6267.
-
Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses. Front Immunol. 2021; 12:653092.